|
Volumn 21, Issue 3, 2012, Pages 327-329
|
Targeting Tumor Architecture to Favor Drug Penetration: A New Weapon to Combat Chemoresistance in Pancreatic Cancer?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
DOXORUBICIN;
ERISMODEGIB;
GEMCITABINE;
HYALURONIC ACID;
HYALURONIC ACID DERIVATIVE;
PEGPH 20;
SONIC HEDGEHOG PROTEIN;
UNCLASSIFIED DRUG;
VISMODEGIB;
ANTINEOPLASTIC ACTIVITY;
APOPTOSIS;
CANCER SURVIVAL;
CARCINOGENESIS;
COLLAPSE;
DRUG DELIVERY SYSTEM;
DRUG PENETRATION;
DRUG TARGETING;
HUMAN;
NONHUMAN;
OVERALL SURVIVAL;
PANCREAS ADENOCARCINOMA;
PRIORITY JOURNAL;
SHORT SURVEY;
SIGNAL TRANSDUCTION;
TISSUE PRESSURE;
TUMOR GROWTH;
TUMOR MICROENVIRONMENT;
TUMOR VOLUME;
|
EID: 84858594444
PISSN: 15356108
EISSN: 18783686
Source Type: Journal
DOI: 10.1016/j.ccr.2012.03.002 Document Type: Short Survey |
Times cited : (70)
|
References (10)
|